Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ORIC.O
stocks logo

ORIC.O

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.380
-25.42%
--
--
-0.410
-2.38%
--
--
-0.429
-8.81%
Estimates Revision
Stock Price
Go Up
up Image
+5.76%
In Past 3 Month
Wall Street analysts forecast ORIC.O stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ORIC.O is 19.10 USD with a low forecast of 15.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast ORIC.O stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ORIC.O is 19.10 USD with a low forecast of 15.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
1 Hold
0 Sell
Strong Buy
Current: 11.390
sliders
Low
15.00
Averages
19.10
High
25.00
Current: 11.390
sliders
Low
15.00
Averages
19.10
High
25.00
Goldman Sachs
initiated
2025-12-04
New
Reason
Goldman Sachs
Price Target
2025-12-04
New
initiated
Reason
Goldman Sachs initiated coverage of Oric Pharmaceuticals with an Early Stage Biotech rating. Oric is a clinical stage biotechnology company with a pipeline of oncology candidates focused on addressing resistance in cancer, the analyst tells investors in a research note.
Evercore ISI
Cory Kasimov
Outperform
initiated
$25
2025-11-20
Reason
Evercore ISI
Cory Kasimov
Price Target
$25
2025-11-20
initiated
Outperform
Reason
Evercore ISI analyst Cory Kasimov initiated coverage of Oric Pharmaceuticals with an Outperform rating and $25 price target. The firm sees a "compelling" opportunity for the company in the "large" prostate cancer market. Oric's lead asset ORIC-944 has the potential to bring a highly effective oral agent across multiple settings, the analyst tells investors in a research note.
JPMorgan
Anupam Rama
maintain
$17 -> $20
2025-11-18
Reason
JPMorgan
Anupam Rama
Price Target
$17 -> $20
2025-11-18
maintain
Reason
JPMorgan analyst Anupam Rama raised the firm's price target on Oric Pharmaceuticals to $20 from $17 and keeps an Overweight rating on the shares. The firm adjusted models in the smid-cap biotech space.
Wolfe Research
Kalpit Patel
Peer Perform
initiated
2025-11-17
Reason
Wolfe Research
Kalpit Patel
Price Target
2025-11-17
initiated
Peer Perform
Reason
Wolfe Research analyst Kalpit Patel initiated coverage of Oric Pharmaceuticals with a Peer Perform rating and no price target. The firm highlights the baseline imbalance in Pfizer's (PFE) mevro study and thinks that the magnitude of benefit may be overstated with the PRC2 inhibitor drug class.
Citi
Buy
maintain
$12 -> $16
2025-11-17
Reason
Citi
Price Target
$12 -> $16
2025-11-17
maintain
Buy
Reason
Citi raised the firm's price target on Oric Pharmaceuticals to $16 from $12 and keeps a Buy rating on the shares following the Q3 report. The firm views the early data for ORIC-944 as promising.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$19 -> $23
2025-11-14
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$19 -> $23
2025-11-14
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Oric Pharmaceuticals to $23 from $19 and keeps a Buy rating on the shares. Oric Pharmaceuticals reported encouraging early-stage results for ORIC-944 combined with apalutamide or darolutamide in heavily pretreated mCRPC, showing PSA50 responses in over half of patients with a favorable safety profile relative to competing combinations, the analyst tells investors in a research note. Ongoing dose optimization will guide the Phase 3 dose selection for a planned 1H26 registrational trial, and the new data support a higher estimated approval probability of 40%, the firm says.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Oric Pharmaceuticals Inc (ORIC.O) is -6.93, compared to its 5-year average forward P/E of -5.45. For a more detailed relative valuation and DCF analysis to assess Oric Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.45
Current PE
-6.93
Overvalued PE
-1.77
Undervalued PE
-9.13

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.12
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.58
Undervalued EV/EBITDA
-6.83

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 496.64% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

ORIC.O News & Events

Events Timeline

(ET)
2025-11-13
17:02:14
Oric Pharmaceuticals Completes Dose Exploration for ORIC-944
select
2025-11-13
16:45:44
Oric Pharmaceuticals announces Q3 earnings per share of 33 cents, below consensus estimate of 40 cents.
select
2025-10-27 (ET)
2025-10-27
08:36:05
Oric Pharmaceuticals Showcases ORIC-944 Posters at EORTC-NCI-AACR Conference
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11:22 AMGlobenewswire
PinnedORIC Pharmaceuticals Reports 80% ORR in 1L EGFR PACC Patients
  • Clinical Trial Results: Enozertinib demonstrated an 80% overall response rate (ORR) and a 100% intracranial response rate (CNS ORR) in 1L EGFR PACC patients, indicating significant efficacy in treating those with active brain metastases, which could redefine treatment standards.
  • Safety Analysis: The safety profile of enozertinib is favorable, with no significant off-target toxicities and treatment-related adverse events (TRAEs) primarily at Grade 1 or 2, resulting in a low discontinuation rate, thereby enhancing patient adherence to treatment.
  • Next Steps: The company plans to update data on 1L EGFR PACC patients in mid-2026 and is considering initiating a potential Phase 3 trial based on these findings, reflecting a positive outlook for future market opportunities.
  • Conference Arrangement: ORIC will host a conference call and webcast on December 6, 2025, to further discuss trial results, enhancing investor confidence in the company's future growth trajectory.
[object Object]
Preview
9.0
12-04Newsfilter
ORIC Pharmaceuticals to Present Enozertinib Data at ESMO Asia Congress 2025
  • Clinical Trial Progress: ORIC Pharmaceuticals will showcase data from its Phase 1b trial of enozertinib (ORIC-114) targeting EGFR mutant NSCLC at the ESMO Asia Congress from December 5-7, 2025, marking a significant milestone in the company's oncology drug development.
  • Presentation Schedule: The company will conduct two key oral presentations focusing on data from previously treated and treatment-naïve patients with EGFR mutations, which is expected to attract significant attention from both industry insiders and the public, enhancing ORIC's visibility in cancer treatment.
  • Webinar Announcement: ORIC will host a conference call and webcast on December 6, 2025, featuring a live Q&A session aimed at sharing the latest research findings with investors and healthcare professionals, thereby strengthening engagement with stakeholders.
  • Diverse Product Pipeline: In addition to enozertinib, ORIC is also developing ORIC-944 for prostate cancer, showcasing the company's broad positioning in treating various genetically defined cancers, which enhances its market competitiveness and investment appeal.
[object Object]
Preview
3.0
12-03Benzinga
Three Health Care Stocks Poised for Significant Gains This December

  • Oversold Stocks Opportunity: The health care sector has several oversold stocks, identified by a Relative Strength Index (RSI) below 30, indicating potential buying opportunities for undervalued companies.

  • Larimar Therapeutics Inc: The company reported a wider-than-expected quarterly loss, with its stock falling 20% over the past month and an RSI of 29.9, closing at $3.12.

  • Perrigo Company PLC: Perrigo's mixed financial results led to a 34% stock decline in the past month, with an RSI of 29.9, closing at $13.61, despite gaining market share in several categories.

  • ORIC Pharmaceuticals Inc: After a recent coverage initiation with an Outperform rating, ORIC's stock fell 16% over the past month, with an RSI of 29.6, closing at $10.65.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Oric Pharmaceuticals Inc (ORIC.O) stock price today?

The current price of ORIC.O is 11.39 USD — it has increased 3.73 % in the last trading day.

arrow icon

What is Oric Pharmaceuticals Inc (ORIC.O)'s business?

ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.

arrow icon

What is the price predicton of ORIC.O Stock?

Wall Street analysts forecast ORIC.O stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ORIC.O is 19.10 USD with a low forecast of 15.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Oric Pharmaceuticals Inc (ORIC.O)'s revenue for the last quarter?

Oric Pharmaceuticals Inc revenue for the last quarter amounts to -36.67M USD, decreased -4.30 % YoY.

arrow icon

What is Oric Pharmaceuticals Inc (ORIC.O)'s earnings per share (EPS) for the last quarter?

Oric Pharmaceuticals Inc. EPS for the last quarter amounts to -25147000.00 USD, decreased -13.92 % YoY.

arrow icon

What changes have occurred in the market's expectations for Oric Pharmaceuticals Inc (ORIC.O)'s fundamentals?

The market is revising No Change the revenue expectations for ORIC for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 5.76%.
arrow icon

How many employees does Oric Pharmaceuticals Inc (ORIC.O). have?

Oric Pharmaceuticals Inc (ORIC.O) has 115 emplpoyees as of December 05 2025.

arrow icon

What is Oric Pharmaceuticals Inc (ORIC.O) market cap?

Today ORIC.O has the market capitalization of 1.11B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free